← Back to search
ARISAN THERAPEUTICS INC
CARLSBAD, CA, 92008
Unclaimed
Source Records
No company-reported description yet. Owners can add one after claiming the profile.
Capabilities
Derived from government recordsGov-sourced
Prime contracting experience
4 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | TO CONDUCT NON-CLINICAL GOOD LABORATORY PRACTICE (GLP) IN VIVO GENOTOXICITY AND REPRODUCTIVE TOXICOLOGY AND GLP DEVELOPMENT AND REPRODUCTIVE (DART) TOXICOLOGY STUDIES. | — | $3,692,037 | Sep 30, 2026 | Sep 22, 2023 – Dec 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | TO DEVELOP A THERAPEUTIC SMALL MOLECULE VIRAL ENTRY INHIBITOR AS A MEDICAL COUNTERMEASURE FOR FILOVIRUS INFECTION. | — | $2,933,547 | Jul 29, 2026 | Aug 3, 2026 – Jun 30, 2027 |
| Prime | Department of Defense Department of the Army | PHASE II BASE PERIOD | — | $526,794 | Aug 23, 2023 | Sep 28, 2021 – Sep 27, 2024 |
| Prime | Department of Defense Department of the Army | PHASE II - SBIR TOPIC CBD192-006 | — | $1,099,662 | Jul 28, 2023 | Sep 30, 2021 – Nov 10, 2023 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
No subaward records on record in current sources. Subcontract relationships are never inferred from award keywords.
Agencies supported
- Department of Health and Human ServicesGov-sourced
- Department of DefenseGov-sourced